HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss.

Abstract
Deletion of acyl-CoA:cholesterol O-acyltransferase 2 (ACAT2) in mice results in resistance to diet-induced hypercholesterolemia and protection against atherosclerosis. Recently, our group has shown that liver-specific inhibition of ACAT2 via antisense oligonucleotide (ASO)-mediated targeting likewise limits atherosclerosis. However, whether this atheroprotective effect was mediated by: 1) prevention of packaging of cholesterol into apoB-containing lipoproteins, 2) augmentation of nascent HDL cholesterol secretion, or 3) increased hepatobiliary sterol secretion was not examined. Therefore, the purpose of these studies was to determine whether hepatic ACAT2 is rate-limiting in all three of these important routes of cholesterol homeostasis. Liver-specific depletion of ACAT2 resulted in reduced packaging of cholesterol into apoB-containing lipoproteins (very low density lipoprotein, intermediate density lipoprotein, and low density lipoprotein), whereas high density lipoprotein cholesterol levels remained unchanged. In the liver of ACAT2 ASO-treated mice, cholesterol ester accumulation was dramatically reduced, yet there was no reciprocal accumulation of unesterified cholesterol. Paradoxically, ASO-mediated depletion of hepatic ACAT2 promoted fecal neutral sterol excretion without altering biliary sterol secretion. Interestingly, during isolated liver perfusion, ACAT2 ASO-treated livers had augmented secretion rates of unesterified cholesterol and phospholipid. Furthermore, we demonstrate that liver-derived cholesterol from ACAT2 ASO-treated mice is preferentially delivered to the proximal small intestine as a precursor to fecal excretion. Collectively, these studies provide the first insight into the hepatic itinerary of cholesterol when cholesterol esterification is inhibited only in the liver, and provide evidence for a novel non-biliary route of fecal sterol loss.
AuthorsJ Mark Brown, Thomas A Bell 3rd, Heather M Alger, Janet K Sawyer, Thomas L Smith, Kathryn Kelley, Ramesh Shah, Martha D Wilson, Matthew A Davis, Richard G Lee, Mark J Graham, Rosanne M Crooke, Lawrence L Rudel
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 283 Issue 16 Pg. 10522-34 (Apr 18 2008) ISSN: 0021-9258 [Print] United States
PMID18281279 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Apolipoproteins B
  • Cholesterol Esters
  • Lipoproteins, LDL
  • Oligonucleotides, Antisense
  • Phospholipids
  • Sterols
  • Cholesterol
  • Sterol O-Acyltransferase
  • sterol O-acyltransferase 2
Topics
  • Animals
  • Apolipoproteins B (metabolism)
  • Biliary Tract (metabolism)
  • Cholesterol (metabolism)
  • Cholesterol Esters (metabolism)
  • Feces
  • Lipoproteins, LDL (metabolism)
  • Liver (metabolism)
  • Male
  • Mice
  • Mice, Knockout
  • Oligonucleotides, Antisense (chemistry)
  • Phospholipids (metabolism)
  • Sterol O-Acyltransferase (genetics, physiology)
  • Sterols (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: